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Abstract 
 
Purpose: 
The main aim of this study was to screen various genetic and non genetic factors which are known 
to alter warfarin response and to generate a model to predict stable warfarin maintenance dose for 
Indian patients.     
Methods: 
The study comprised of 300 warfarin treated patients. Followed by extensive literature review, 10 
single nucleotide polymorphisms (SNPs) i.e. VKORC1-1639 G>A (rs9923231), CYP2C9*2 
(rs1799853), CYP2C9*3 (rs1057910), FVII R353Q (rs6046), GGCX 12970 C>G  (rs11676382), 
CALU c.*4A>G (rs1043550),  EPHX1 c.337T>C  (rs1051740),  GGCX:  c.214+597G>A 
(rs12714145), GGCX: 8016G>A (rs699664) and CYP4F2 V433M (rs2108622) and 5 non genetic 
factors i.e. age, gender, smoking, alcoholism and diet were selected to find their association with 
warfarin response. 
Results: 
The univariate analysis was carried out for 15 variables (10 genetic and 5 non genetic). Five 
variables i.e.VKORC1 -1639 G>A, CYP2C9*2, CYP2C9*3, age and diet were found to be 
significantly associated with warfarin response in univariate analysis. These five variables were 
entered in stepwise and multiple regression analysis to generate a predication model for stable 
warfarin maintenance dose. The generated model scored R
2
 of 0.67 which indicates that this model 
can explain 67% of warfarin dose variability.  
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Conclusion: 
 
The generated model will help in prescribing more accurate warfarin maintenance dosing in Indian 
patients and will also help in minimizing warfarin induced adverse drug reactions and a better 
quality of life in these patients. 
 
Key words: Warfarin, Dosing algorithm, Multiple regression analysis, India. 
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Introduction 
 
The goal of pharmacogenetics is to predict patient’s response to a specific drug, based on the 
genetic variations, in order to deliver the best possible medical treatment. Prediction of the drug 
response of an individual can increase the success of therapies and reduce the incidence of adverse 
side effects. Till date numerous single-nucleotide polymorphisms are identified in genes coding 
for liver enzymes responsible for drug deposition and pharmacokinetics. Warfarin (coumarin) 
therapy is one of the many clinical situations in which knowledge of pharmcogenomics can deliver 
safe personalized dosing. 
Several evidences indicate that major genetic variables responsible for individual pharmacological 
response to warfarin are polymorphisms in two genes namely, Vitamin K epoxide reductase 
complex subunit 1 (VKORC1) and Cytochrome P450-2C9 (CYP2C9).
1-5
 Genetic variations in 
Cytochrome P450-4F2 (CYP4F2), Gamma-glutamyl carboxylase (GGCX), Epoxide hydrolase 1 
(EPHX1), Calumenin (Calu), Factor IX (F9) and Factor VII (F7) gene also have shown subsidiary 
association with warfarin response.
6-12
 Other non-genetic factors including ethnicity, age, body 
mass index (BMI), weight and gender are also known to have a minor role in warfarin sensitivity.13-
19 Based on pharmacogenetics, clinical and demographic factors, population based warfarin 
pharmacogenomic algorithms have been generated for various ethnic groups. 20-22 
In this study, we aim to generate a predication model for stable warfarin maintenance dose in 
Indian patients by comprehensive analysis of genetic and non genetic factors using multiple linear 
regression model. The outcome of such study will help in prescribing more accurate warfarin 
dosing and will improve management of this challenging therapy by minimizing warfarin induced 
adverse drug reactions in Indian patients. 
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Materials and Methods 
 
This study comprised of 300 patients who were prescribed warfarin for various clinical conditions. 
Patients were recruited from King Edward Memorial Hospital, Mumbai; BYL Nair Charitable 
Hospital, Mumbai as well as clinics located in Mumbai and other parts of India. The study was 
approved by the Institutional Ethics Committee Review Board for Research on Human Subjects 
of National Institute of Immunohaematology (ICMR). Patients on any other medication known to 
interact with warfarin and patients with abnormal renal or liver function test were excluded from 
the study. A clinical proforma was designed to include all the relevant patient information like 
International normalized ratio (INR) values, warfarin daily dose, changes in warfarin dose, gender, 
body weight, height, smoking, diet, race, bleeding complications, new thrombotic 
episodes, surgical procedures or any other major health complications. Warfarin initiation and 
maintenance dose adjustment was blinded to genotype results. Initially INR was tested every 2-4 
days. After 2 consecutive therapeutic INR, testing interval was increased to 2 weeks. After 4 
consecutive therapeutic INR, this was increased to 4 weeks and continued with the same 
monitoring interval. 
The minimum follow up period was 6 months and the maximum period was 15 months. None of 
the patients were on any vitamin K supplements. 
Operational Definitions: 
 
Overanticoagulation: A patient was said to be overanticoagulated if patient’s INR was > 4.0. 
 Bleeding episodes: Patients were considered to have “bleeding episodes” when it required medical 
attention or attendance at hospital. 
Alcoholism: We categorized weekly alcohol intake as light (1-6 drinks), moderate (7-13 drinks), 
and Chronic (> or =14 drinks). 
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Diet: Patients who have non-vegetarian diet two or more times in a week were included in non-
vegetarian category whereas patients who avoid all food derived from animals or patients who 
occasionally eat non-vegetarian diet were included in vegetarian/ occasionally non-vegetarian 
category. 
Selected variables: 
 
Followed by extensive literature review, 10 single nucleotide polymorphisms (SNPs) i.e. 
VKORC1-1639 G>A (rs9923231), CYP2C9*2 (rs1799853), CYP2C9*3 (rs1057910), FVII R353Q 
(rs6046), GGCX 12970 C>G (rs11676382), CALU c.*4A>G (rs1043550), EPHX1 c.337T>C 
(rs1051740), GGCX: c.214+597G>A (rs12714145), GGCX: 8016G>A (rs699664) and CYP4F2 
V433M (rs2108622) and 5 non genetic factors i.e. age, gender, smoking, alcoholism and diet were 
selected to see their association with warfarin dose requirement and risk of overanticoagulation. 
 
Blood collection and processing 
 
After obtaining informed consent, 10 ml of venous blood sample was collected in 3.13% sodium 
citrate (1:9 anticoagulant to blood) from each patient. The samples were spun at 4000 rpm for 15 
minutes at 4
0
C. The platelet poor plasma was used for PT-INR test. Usually the test is performed 
within 1 hour of collection of blood. The cell pellet was preserved at -20
0
C for DNA analysis. 
DNA was extracted by standard phenol chloroform method. 
Genotyping 
The PCR amplification was done using oligonucleotide primers (Sigma Chemicals, Bangalore, 
India) in a 96 welled thermal cycler (Applied Biosystems, Carlsbad, California). Genotyping for 
10 SNPs was carried out by restriction fragment length polymorphism (RFLP), allele specific PCR 
and direct sequencing method. 
 
 
 
6 
 
http://mc.manuscriptcentral.com/cath 
Page 7 of 30 Clinical and Applied Thrombosis/Hemostasis 
 
 
1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60 
 
 
 
Restriction fragment length polymorphism: 
VKORC1-1639 G>A (rs9923231), CYP2C9*2 (rs1799853), CYP2C9*3 (rs1057910) and FVII 
R353Q (rs6046) polymorphisms were genotyped using RFLP technique. 
Briefly, the protocol for DNA amplification was as follows; the PCR mix consisted of a final 
volume of 25 µl, containing 1.25 µl of 10 pmol each primers, 0.2 µl 25 mM deoxynucleotides 
triphosphate, 1.5 µl 25 mM MgCl2, 2.5 µl 10X complete buffer (Bioron, Ludwigshafen, Germany), 
0.15 µl DFS- Taq DNA polymerase. (Bioron, Ludwigshafen, Germany) and 2 µl DNA sample. 10 
µl of amplified product was used for RFLP analysis using 5 units of Hpa II, Ava II, Nsi I and Msp 
I restriction enzyme (New England Biolabs, Hertfordshire, UK) for VKORC1 -1639 G/A, 
CYP2C9*2, CYP2C9*3 and FVII R353Q genotypes respectively. 
The PCR program and the primer sequences for genotyping are given in supplementary file, Table 
S1 (Online Resource 1). 
 
Allele Specific PCR method: 
Following polymorphisms were genotyped by allele specific PCR standardized in the laboratory: 
CALU c.*4A>G (rs1043550), CYP4F2 V433M (rs2108622), EPHX1 c.337T>C (rs1051740), 
GGCX c.214+597G>A (rs12714145) and GGCX 8016G>A (rs699664). Two primers were 
designed, one specific for the wild type and the other for variant, to specifically detect desired 
genotypes. PCR conditions were standardized with known wild type, heterozygous and 
homozygous samples. The accuracy of standardized allele specific PCR method was validated 
with direct sequencing method and the data was in agreement. 
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Direct Sequencing: 
GGCX 12970 C>G (rs11676382) polymorphism was genotyped by direct sequencing 
method. The DNA samples were amplified using oligonucleotide primers in a 96 welled thermal 
cycler (Applied Biosystems Veriti, Carlsbad, California). Briefly, the protocol for DNA 
amplification was as follows; In a final volume of 25 µl, containing 1.25 µl of 10 pmol each 
primers, 0.2 µl 25 mM deoxynucleotides triphosphate, 0.5 µl 25 mM MgCl2, 2.5 µl 10X complete 
buffer (Bioron, Ludwigshafen, Germany), 0.10 µl DFS- Taq DNA polymerase (Bioron, 
Ludwigshafen, Germany) and 2 µl DNA sample. Primer sequences and PCR program for the same 
are given in supplementary file, Table S2 (Online Resource 1).Amplified PCR products were 
purified using commercial kits (Invitrogen, city, USA) followed by cycle sequencing using 
BigDye Terminator v3.1 cycle sequencing kit. Sequencing was performed on an ABI Prism 
Genetic analyzer. 
Statistical Analysis: 
Hardy-Weinberg equilibrium was estimated for all the analyzed polymorphisms using an Excel 
based application (Microsoft Office 2007).  
Fisher’s exact test was used to calculate the p value. Data was shown to be significant if p value 
was ≤0.05, 95% confidence interval (CI). Statistical analysis for Fisher’s exact was performed 
with the MedCalc Software Version 12.3.0 (http://www. 
medcalc.org/calc/relative_risk.php). In most cases, the mutant homozygotes and heterozygotes 
were combined and compared to the wild type. For CYP2C9, each mutant genotype was compared 
to the wild type. Warfarin dose was square rooted before analysis to approximately normalise the 
data and to equalise the variance.  Univariate analysis was done using one way ANOVA or t-tests 
(2 groups) on the square root of dose.  
Multiple Regression Analysis: Stepwise multiple regression analysis was carried out using 
statistical program ‘R’ (version 3.1.3).      
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Results 
 
 
A total of 300 patients fitting into the inclusion criteria were screened for 15 variables. The 
demographic and clinical data is shown in table 1.  
59% were males and age range was from 19 to 80 years. The mean daily stable warfarin dose was 
5.05 (±1.84 mg). Cerebral venous thrombosis and lower limb deep vein thrombosis (DVT) were 
the commonest types of thrombosis. 
Univariate analysis: 
Univariate analysis was carried out to evaluate the association of genetic and non genetic variables 
with warfarin response. 
A) Genetic factors: The genotype frequencies of all the polymorphisms and their effect on 
warfarin dose requirement and risk of overanticoagulation are shown in table 2. Among the 10 
polymorphisms analyzed, VKORC1-1639 G>A polymorphism showed significant association 
with reduced dose requirement and risk of overanticoagulation (P<0.001). The ‘A’ allele carriers 
were found to require low warfarin dose and were posed with higher risk of overanticoagulation. 
Among the two CYP2C9 variants, CYP2C9*3 variant allele carrier patients showed statistically 
significant association with lower dose requirement as well as risk of overanticoagulation 
(P<0.001), while CYP2C9*2 allele carrier patients showed relatively weak association (P<0.05) 
as compared to CYP2C9*3, but it was statistically significant. CALUc.*4A>G (rs1043550), 
EPHX1 c.337T>C (rs1051740), CYP4F2 V433M (rs2108622), GGCX104+597 G>A 
(rs12714145), GGCX 8016G>A (rs699664), and Factor VII R353Q (rs6046) polymorphisms 
showed nonsignificant association with dose requirement and also no statistical significant 
association was found with risk of overanticoagulation. GGCX 12970 C>G (rs11676382) variant 
allele was found to be absent in the present series. 
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 B) Non genetic factors: 
Five non genetic factors i.e. age, gender, smoking, alcoholism and diet were selected, to study their 
association with warfarin dose requirement and risk of overanticoagulation (Table 3). Among the 
non-genetic factors, age was found to have significant association with risk of over-anticoagulation 
(<60 years versus ≥60 years, p<0.001). When the two age groups were compared, there was no 
significant difference in warfarin dose. However it was significant across all age groups (P=0.013). 
With increasing age, the requirement of warfarin dose reduced but the risk of over-anticoagulation 
significantly increased in elderly patients. Gender and smoking were neither found significantly 
associated with overanticoagulation nor with dose requirement. Though, in the current study 
alcoholism has not shown any association with warfarin dose requirement or risk of 
overanticoagulation, yet the effect of alcoholism on warfarin is unclear in this study, as many 
chronic alcoholic patients with liver dysfunction and abnormal liver function were excluded from 
the present study. Vegetarian or occasionally non-vegetarian patients were found to require 
significantly lower warfarin dose as compared to non-vegetarian patients (p=0.013).  However, no 
significant association was found with the risk of overanticoagulation. 
Multiple linear regression analysis 
Multiple regression analysis was carried out to generate a model to predict stable warfarin 
maintenance dose. All possible explanatory variables were considered but only i.e.VKORC1-1639 
G>A, CYP2C9*2, CYP2C9*3, age and diet were found significant in a stepwise multiple linear 
regression model (Table 4). Based on the multiple regression analysis the following equation was 
generated to predict daily stable warfarin maintenance dose in Indian patients: 
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Square root of dose (mg) = 2.61 - 0.41 (VKORC1-1639) - 0.21 (*1/*2) - 0.58 (*1/*3) - 0.86 
 
(*2/*3) - 0.86 (*3/*3) - 0.002 (Age in years) - 0.08 (diet) 
 
 
 VKORC1-1639: ‘0’ for GG, ‘1’ for GA, ‘2’ for AA

 CYP2C9 *1/*2, *1/*3, *2/*3 and *3/*3, ‘0’ if variant genotype is absent, 
and ‘1’ if variant genotype is present. 

 ‘0’ if patient is Non vegetarian, and ‘1’ if patient is vegetarian or occasionally non-
vegetarian.
 
R
2
 of the multiple regression model was scored to 0.67, indicating that the prediction model could 
explain approximately 67% of dose variability. The maximum dose variability was explained by 
CYP2C9 (*2 and *3) and VKORC1 genotypes i.e. 42% and 23% respectively, followed by age 
and diet (table 5).  
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Discussion 
 
The pharmacogenetic data has been helping the clinicians in improving the patient care by way of 
reduction in adverse drug reactions or by decreasing the cost of treatment by minimizing hospital 
admissions. The aim of our study was to develop a model for prediction of stable warfarin 
maintenance dose in Indian patients. In the present study out of 15 analyzed markers only 5 
markers i.e. CYP2C9*2, CYP2C9*3, VKORC1 -1639 G>A, age and diet were found to be 
significantly associated with warfarin response in univariate analysis. 
Many studies have reported that, VKORC1 and CYP2C9 polymorphisms are the major predicating 
factors of warfarin dose requirement but the present study shows that integrating patient’s diet and 
age can marginally improve the power of dose prediction. It is reported that a vitamin K rich diet 
can prevent the action of warfarin (vitamin K antagonist) and may need high warfarin maintenance 
dose.23-25 Whereas, Ford et al (2007) in a review of literature concluded that Vit K supplementation 
may reduce variation in drug response caused by dietary intake.26 Few other studies have suggested 
that patients on warfarin need to maintain consistent dietary vitamin K intake to achieve more 
stable anticoagulation response.23,27 In the present study, non vegetarian patients were found to 
require high warfarin dose than the vegetarian patients.  
Reports have shown that warfarin dose is inversely proportional to age and also elderly patients 
(>75 years of age) are at more risk for bleeding complications (P<0.05).
18,28-30
 In the present study, 
significant association of age with decreased warfarin dose requirement was observed and a linear 
trend across all ages was seen (P<0.05). The risk of warfarin induced bleeding was also significant 
when compared between the two age groups i.e. <60 years versus ≥60 years (p<0.001). 
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The generated prediction model scored R
2
 to 0.67, indicating that this predication model could 
explain nearly 67% dose variability. The prediction power of this study is quite good as compared 
to other reported prediction models in Indian patients.
31-34
 However, the remaining 33% dose 
variability is still unsolved. It might be due to the genetic and/or non genetic factors which are yet 
to be identified. More well designed and large scale studies are needed to uncover these unknown 
factors affecting warfarin response. Though this is a comprehensive analysis of most of the 
genetic and non-genetic risk factors associated with warfarin sensitivity, yet there is a lack of 
systematic data on co-medications and other comorbidities associated with warfarin response. For 
instance, though alcohol intake has been considered as one of the factors in the present analysis, 
chronic alcoholics with liver dysfunction had to be excluded from the present study. Although, the 
generated model can predict warfarin dose modestly and not the exact dosing, it can still help in 
dividing patients into low, intermediate and high dose requirement groups which will help in 
prescribing more appropriate stable warfarin maintenance dosage than the conventional dosing 
and will also help in minimizing warfarin induced adverse drug reactions and a better quality of 
life in patients who are treated with warfarin. 
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Table 1: Demographic and clinical data 
 
Total number of patients: 300 
 
 
Male, n (%) 177 (59) 
   
Female, n (%) 123 (41) 
  
Age, years [Median (range)] 37 (19-80) 
  
BMI (kg/m
2
) [Median (range)] 
22.10 (17.12-
35.42) 
  
Duration of anticoagulant treatment, months [Median (range)] 6 (6-24) 
  
Stable average daily warfarin dose (mg) mean (standard deviation) 5.05 (±1.84) 
   
Indication for anticoagulation with warfarin, n (%)   
  
Atrial fibrillation 8 (2.7) 
   
Cerebral venous thrombosis 111 (37.0) 
   
Lower limb DVT 123 (41) 
  
Upper limb DVT 10 (3.3) 
  
Heart valve replacement 37 (12.4) 
  
Young stroke 7 (2.3) 
  
Others 4 (1.3) 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 2: Effect of genetic polymorphisms on warfarin dose requirement and risk of over 
anticoagulation. 
 
Polymorphism Genotype 
N=300 
N (%) 
Mean 
daily 
warfarin 
dose 
(mg/day) 
*P values 
for Mean 
daily 
warfarin 
dose 
Patients faced 
over 
anticoagulation 
(INR>4) 
N (%) 
P values for 
over 
anticoagulat
ion 
(INR>4) 
VKORC1- 
1639G>A 
(rs9923231) 
GG 223 (74) 5.55 - 86 (39) - 
GA 
73 
(25) 
3.68 
P<0.001 
42 (58) 
P<0.001 
AA 4 (1) 2.12 4 (100) 
CYP2C9 
genotype 
(rs1799853) 
(rs1057910) 
*1/*1 
211 
(71) 
5.81 - 68 (32) - 
*1/*2 15 (5) 4.42 
P<0.001 
8 (53) 
P<0.001 
*1/*3 60 (20) 3.18 43 (72) 
*2/*3 4 (1) 2.68 3 (75) 
*3/*3 10 (3) 2.2 10 (100) 
CALU c.*4A>G 
(rs1043550) 
AA 
182 
(61) 
5.02 - 77 (43) - 
GA 
97 
(32) 
5.07 
P=0.881 
45 (46) 
P= 0.4602 
GG 21 (7) 5.19  10 (48) 
EPHX1 
c.337T>C 
(rs1051740) 
TT 129 (43) 5.09 - 75 (46) - 
TC 140 (47) 5.03 
P= 0.97 
30 (43) 
P= 0.4459 
CC 31(10) 4.97 27 (40) 
GGCX  
c.214+597 G>A 
(rs12714145) 
GG 
163 
(54) 
5.09 - 75 (46) - 
GA 
70 
(24) 
4.87 
P= 0.64 
30 (43) 
P= 0.4459 
AA 
67 
(22) 
5.14 27 (40) 
GGCX 12970 
C>G  
(rs11676382) 
CC 
300 
(100) 
5.05 - 132 (44) - 
CG - - 
  
- 
NA**  
GG - - - 
GGCX  
8016G>A  
(rs699664) 
GG 
97 
(32) 
5.07  - 40 (41) - 
GA 
185 
(62) 
5.04 
 P=0.953 
85 (46) 
P= 0.5110 
AA 18 (6) 5.01 7 (39) 
CYP4F2 
V433M 
(rs2108622) 
GG 
93 
(31) 
4.99 - 41 (44) - 
GA 
178 
(59) 
5.03 
P=0.505 
75 (42) 
P= 0.9839 
AA 
29 
(10) 
5.38 16 (55) 
FVII R353Q 
13407G>A 
(rs6046) 
GG 
167 
(56) 
5.15 - 66 (39) - 
GA 
122 
(40) 
4.86 
P=0.213 
64 (52) 
P= 0.0790 
AA 11 (4) 5.63 2 (18) 
*P-values for warfarin dose denote the result of one way ANOVA on the square root of dose. 
** Variant allele not present 
  
Table 3: Effect of non-genetic factors on warfarin dose requirement and risk of over 
Anticoagulation. 
Characteristic Parameters 
N=300 
(%) 
Mean 
daily 
warfarin 
dose 
(mg/day) 
*P values 
for Mean 
daily 
warfarin 
dose 
Patients 
who faced 
overantico
agulation 
(INR>4) 
N(%) 
P values 
for 
overantico
agulation 
(INR>4) 
Age 
< 60 years 279 (93) 5.07 - 115 (41) - 
≥60 years 21 (7) 4.74 P=0.53 17 (81) P<0.001 
Gender 
Male 177 (59) 4.95   77 (43)   
Female 123 (41) 5.19 P=0.338 55(43) P = 0.8348 
Smoking 
No 268 (89) 5.05 - 121 (45) - 
Yes 32 (11) 5.01 P=0.686 11 (34) P=0.2819 
Chronic 
Alcoholic 
No 260 (87) 5.02 - 119 (46) - 
Yes 40 (13) 5.24 P=0.888 13 (32) P=0.1497 
Diet 
Non 
vegetarians 
214 (71) 5.23 - 92 (43) - 
Vegetarian or 
occasionally 
non-
vegetarian 
86(29) 4.61 P=0.013 40 (47) P=0.5736 
 
*P-values for warfarin dose relate to t-tests on the square root of the dose
                    
Table 4: Multiple linear regression analysis 
 
Coefficients: Estimate Standard Error Pr(>|t|) 
(Intercept) 2.609832 0.046119 < 2e-16 *** 
VKORC1- 1639 G>A -0.40674 0.030869 < 2e-16 *** 
CYP2C9*1/*2 -0.206816 0.068246 0.00266** 
CYP2C9*1/*3 -0.579309 0.037153 < 2e-16 *** 
CYP2C9*2/*3 -0.862982 0.126904 5.93e-11 *** 
CYP2C9*3/*3 -0.864116 0.081463 < 2e-16 *** 
Age -0.002576 0.001103 0.02023* 
Vegetarian -0.082231 0.032153 0.01105* 
Significance codes: ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1 
 
 
  
Table 5: Contribution of factors in multiple linear regression model 
 
Predictor Partial R2 (%) P value 
VKORC1- 1639 G>A 23% P<0.001 
CYP2C9*2 and CYP2C9*3 
genotype 
42% P<0.001 
Age 0.80% P<0.01 
Diet 0.70% P<0.05 
Model R
2
 67% P<0.001 
 
 
